BCCA Protocol Summary for Treatment of Malignant Mesothelioma with Vinorelbine

*Protocol Code:* LUMMVIN
*Tumour Group:* Lung
*Contact Physician:* Dr. Christopher Lee

**ELIGIBILITY:**
- First-line treatment in individuals not candidates for platinum-based combination chemotherapy
- Second-line treatment in individuals previously treated with platinum-based combination chemotherapy

**EXCLUSIONS:**
- More than one previous chemotherapy regimen

**TESTS:**
- Baseline: CBC & differential, platelets, creatinine, liver function tests, bilirubin
- Before each treatment: CBC & differential, platelets
- If clinically indicated: creatinine, bilirubin prior to each cycle

**PREMEDICATIONS:**
- See antiemetic guidelines for Rare emetogenic chemotherapy (see protocol SCNAUSEA). Antiemetics are not usually required. Prescribe according to patient specific symptoms.
- Hydrocortisone 100mg IV prior to vinorelbine if patient experiences pain on administration

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vinorelbine</td>
<td>30 mg/m²/day on days 1 and 8</td>
<td>IV in 50 mL NS over 6 minutes</td>
</tr>
</tbody>
</table>

Repeat every 21 days x 6 cycles
DOSE MODIFICATIONS:

1. Hematological:

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Vinorelbine Dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.0</td>
<td>and</td>
<td>greater than 100</td>
</tr>
<tr>
<td>0.5-1.0</td>
<td>or</td>
<td>75-100</td>
</tr>
<tr>
<td>less than 0.5</td>
<td>or</td>
<td>less than 75</td>
</tr>
</tbody>
</table>

*Consider decreasing vinorelbine to 75% or 22.5mg/m^2 if an episode of febrile neutropenia occurs with the prior cycle of treatment.

2. Hepatic dysfunction:

<table>
<thead>
<tr>
<th>Bilirubin (micromol/L)</th>
<th>Vinorelbine Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than or equal to 35</td>
<td>100%</td>
</tr>
<tr>
<td>36-50</td>
<td>50%</td>
</tr>
<tr>
<td>greater than 50</td>
<td>25%</td>
</tr>
</tbody>
</table>

PRECAUTIONS:

1. Extravasation: Vinorelbine causes pain and tissue necrosis if extravasated. It is recommended to flush thoroughly with 75-125 mL NS after infusing vinorelbine. Hydrocortisone 100mg IV prior to vinorelbine may be of benefit. Refer to BCCA Extravasation Guidelines.

2. Neutropenia: Fever or other evidence of infection must be assessed promptly and treated aggressively.

Call Dr. Christopher Lee or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 1 Mar 2009 (replacing LUVIN)

Date revised: 01 June 2011 (Infusion section revised)

REFERENCES:
